Welcome to our dedicated page for CANSORTIUM news (Ticker: $CNTMF), a resource for investors and traders seeking the latest updates and insights on CANSORTIUM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CANSORTIUM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CANSORTIUM's position in the market.
Cansortium Inc. reported strong financial results for Q4 and full year 2023, with record revenue, positive cash flow, and growth in key markets. Revenue increased 9% YoY to $25.5 million in Q4 and 11% to $97.3 million for the full year. Adjusted gross profit was $49.5 million, with $27.2 million in adjusted EBITDA for the year. The Company remains focused on operational improvements, expansion in Florida and Pennsylvania, and growth in Texas.